Avelumab and Merkel Cell Carcinoma: Biological Plausibility Explained

From General Health Science to Targeted Therapy Concerns

The legacy of general health and science information has long served as a foundation for public understanding of disease prevention and treatment. Within this broad context, discussions of therapeutic interventions and their potential consequences have been framed in terms of population-level benefits and risks. As this heritage evolved, the focus gradually shifted from abstract health principles to specific clinical scenarios, including the use of biologic agents in oncology. Avelumab, a programmed death-ligand 1 inhibitor, emerged as a therapeutic option for certain malignancies, with its mechanism of action centered on immune system modulation. This transition from general health discourse to targeted therapy naturally raises questions about unintended effects, particularly in occupational settings where exposure to such agents may occur. The pivot from a clinical context to an occupational exposure concern is grounded in the recognition that workers handling these substances—pharmaceutical manufacturing personnel, healthcare workers, or laboratory staff—may face distinct risk profiles. Understanding the biological plausibility of any association between avelumab exposure and subsequent disease development requires careful consideration of exposure routes, duration, and individual susceptibility factors. This shift in perspective moves beyond patient-centered discussions to encompass workplace safety and occupational health surveillance.

Avelumab's Mechanism and Clinical Context

Avelumab is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It is approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/29799096/). The approval was based on the JAVELIN Merkel 200 trial, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). Despite these benefits, immune checkpoint inhibitors including avelumab are known to cause overactivation of the immune system, leading to immune-related adverse events (irAEs) (https://pubmed.ncbi.nlm.nih.gov/31543781/). This raises the question of whether avelumab can cause or contribute to the development of Merkel cell carcinoma itself, rather than merely being used to treat it. The biological plausibility of avelumab-related Merkel cell carcinoma causation must be examined through mechanistic pathways, clinical timelines, and safety-communication contexts.

Evidence on Causation and Risk Context

First, it is important to note that MCC is associated with chronic exposure to ultraviolet light and the Merkel cell polyoma virus (https://pubmed.ncbi.nlm.nih.gov/35877101/). Avelumab's mechanism of action involves blocking PD-L1, thereby enhancing T-cell activity against tumor cells. However, this immune activation can also lead to unintended consequences, such as the reactivation of latent infections or the induction of autoimmune-like conditions. For example, a case report describes hypercalcemia due to reactivation of sarcoidosis during avelumab treatment for metastatic MCC, which was managed with corticosteroids and allowed continuation of avelumab therapy (https://pubmed.ncbi.nlm.nih.gov/31543781/). This demonstrates that avelumab can trigger immune-mediated events that are not directly related to the target tumor. In the context of MCC causation, the key question is whether avelumab could induce de novo MCC or accelerate its progression. The evidence does not support a direct causal link. Avelumab is used to treat existing MCC, and its approval is based on its efficacy in reducing tumor burden. However, the possibility of avelumab contributing to MCC development in a previously unaffected individual is biologically implausible given its mechanism. Immune checkpoint inhibitors like avelumab work by releasing brakes on the immune system, which typically helps control cancers, including virus-driven ones like MCC associated with Merkel cell polyoma virus. There is no known pathway by which PD-L1 inhibition would initiate the oncogenic transformation of Merkel cells. Instead, the risk is that avelumab may be ineffective in some patients, leading to disease progression. Indeed, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). For avelumab-refractory patients, alternative treatments such as ipilimumab plus nivolumab have shown activity, with three out of five patients in one study responding to combined therapy according to RECIST 1.1 (https://pubmed.ncbi.nlm.nih.gov/33439294/). Another multicenter study reported response rates to PD-1/PD-L1 inhibition of up to 62% in metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/36450381/), indicating that while many patients benefit, a substantial proportion do not. From a causation-focused clinical interpretation, the timeline between avelumab exposure and documented health outcomes is critical. In the JAVELIN Merkel 200 trial, responses were assessed over time, and adverse events were monitored. There are no reported cases in the provided evidence of avelumab causing new-onset MCC in patients without prior MCC. Instead, the evidence focuses on avelumab's role in treating MCC and managing refractory disease. The safety-communication context regarding avelumab and MCC emphasizes its therapeutic use, not a causative role. Regulatory approvals and clinical guidelines position avelumab as a treatment for MCC, not a risk factor for its development. In summary, based on the available evidence, there is no biological plausibility for avelumab causing Merkel cell carcinoma. The drug is an effective treatment for MCC, and its immune-related adverse events, while significant, do not include induction of MCC. The risk narrative for affected patients should focus on the potential for avelumab to be ineffective or to cause irAEs, rather than causing the cancer itself. Clinicians should monitor for disease progression and manage irAEs appropriately, but there is no evidence to support a causal link between avelumab exposure and MCC development.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified medical contexts for case-specific decisions.

Frequently Asked Questions

Can avelumab cause Merkel cell carcinoma?

Based on current evidence, there is no biological plausibility for avelumab causing Merkel cell carcinoma. Avelumab is an immune checkpoint inhibitor used to treat existing MCC, and its mechanism of action does not support induction of new cancers. Instead, it may be ineffective in some patients, leading to disease progression.

What are the risks of avelumab therapy?

Avelumab can cause immune-related adverse events (irAEs) due to overactivation of the immune system, such as reactivation of sarcoidosis (https://pubmed.ncbi.nlm.nih.gov/31543781/). However, it does not cause MCC. The primary risk is that approximately 50% of patients with advanced MCC may not respond to therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/).

Does submitting information create an medical context-client relationship?

No. Submission requests an initial records screening only and does not create an medical context-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.